Syngene International Ltd., a global contract research, development and manufacturing organization (CRDMO), launched its new protein production platform. The platform, using a cell line and transposon-based technology in-licensed from Swiss biotech services company, ExcellGene, coupled with Syngene’s clone selection and development processes, aims to provide significant improvement in efficiency and precision. The new platform offers enhanced protein production, enabling quicker preclinical and clinical development as well as product launches. 
 
The new platform is designed to streamline clone selection and enhance operational productivity. It also supports a wide range of biomolecules including monoclonal antibodies, biosimilars, bispecifics, antibody-drug conjugates and other recombinant proteins. This versatility facilitates integration with both perfusion and fed-batch manufacturing processes. By combining this technology with Syngene’s existing capabilities, the company now offers a full range of cell line development options using the latest technology.
 
“Syngene sees biologics as a key driver of future growth and we are committed to investing in cutting-edge technology to achieve reliability, precision and speed for clients. By combining Syngene’s skills and experience with ExcellGene’s best-in-class cell line development technology, we can expedite getting molecules to market for the people and patients who need them,” said Alex Del Priore, Senior Vice President, Manufacturing Services, Syngene International.
 
“High yield manufacturing is a multifactorial exercise that starts with transfections and an optimised cell host. We are delighted to partner with and to contribute to Syngene’s process development and manufacturing capabilities. This will leverage our technology and our cells (CHOExpress) for the benefit of their extensive client base. At ExcellGene, we pride ourselves in having studied the profound challenges in DNA transfer to cultivated cells for decades and linked insights from such studies to their phenotypes and use in manufacturing,” said Maria J. and Florian M. Wurm, Cofounders and Managers, ExcellGene.